FKGK11 

FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2). FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis^[1][2].

FKGK11 在 0.091 摩尔分数下对 GVIA iPLA2 的抑制率为 99.4%，而对 GV sPLA2 的抑制率仅为 28%^[1]。
FKGK11 可降低 EOC (上皮性卵巢癌) 细胞的粘附、迁移和侵袭^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

FKGK11 可抑制异种移植小鼠模型中的肿瘤发展^[2]。
FKGK11 在 cPLA2 GIVA / 小鼠和 C57BL/6 小鼠中显示巨噬细胞数量和髓鞘破坏的退化纤维数量显著增加^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

280.23

C₁₃H₁₃F₅O

1071000-98-0

液体

Colorless to light yellow

Room temperature in continental US; may vary elsewhere.

Solution, -20°C, 2 years

• [1]. Kokotos G, et al. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.  [Content Brief]

  [2]. Yan Xu, et al. Abstract 3525: Targeting Group VIA phospholipase A2 using small molecules for ovarian cancer treatment. Cancer Res (2011) 71 (8_Supplement): 3525.

  [3]. López-Vales R, et al. Intracellular phospholipase A(2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury. Brain. 2008 Oct;131(Pt 10):2620-31.  [Content Brief]